Ann: US FDA grants Orphan Drug Designation for CRO-67, page-61

Thanks. Okay so they had $3m in cash and established a $2m standby credit facility 'just in case' which they may not need to use, until the R&D & other receivables of $6m are banked.

So effectively as at 30 June 2023 they have $9m of their own cash plus a $2m line of credit which may not cost them anything if they choose not to use it.

I can see potential for a deep pocketed partner stepping up to fund the development and future trials of CRO-67 and so probably no immediate need to raise funds, although they may choose to do anyway.

I have now changed my position (which I forgot to do previously) as sadly I recently sold out of my holdings at a massive loss but wish existing holders the best of luck all the same.